Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy
Chimeric antigen receptor T cell (CAR-T) therapy targeting GD2 in osteosarcoma and neuroblastoma in a Phase I clinical trial shows feasibility and safety but limited efficacy. Kaczanowska et al. analyze baseline, product and post-treatment patient samples and demonstrate myeloid and T cell phenotypes associated with CAR-T expansion.